More Industry still facing Problems with Root Cause Investigations
More USP with new Chapter on Supplier Qualification and Guidance for associated Risk Assessments
More FDA Warning Letter on Significant Data Integrity Issues at Chinese Manufacturer
More FDA gets expanded Power to prevent Medical Device Supply Disruptions
More Final EMA Guideline: Quality Requirements for Combination Products
More EMA adopts final Public Statement on Pyrrolizidine Alkaloids
More API Testing in the Focus of the Inspections of the U.S. FDA
More GDP Non-Compliance Report for German Wholesale Distributor: RP is not Continuously Contactable
More New MHRA Inspectorate Blog GDP Post: Protecting the UK Medicines Supply Chain
More FDA sends Warning Letter to Australian OTC Drug Products Manufacturer
More FDA Warning Letter due to contaminated Hand Disinfectants